作者: Karen Cravero , Ben Ho Park
DOI: 10.1007/S12609-016-0199-2
关键词:
摘要: Recent studies suggest circulating cell-free tumor DNA offers advantages compared to tissue biopsies for mutation profiling. This concept of “liquid biopsy” allows a more global genomic picture metastatic disease since blood serves as reservoir all sites. In addition, can be measured quantitatively, presenting the possibility using biomarker measure burden and response therapies. Here, we review historic recent demonstrating clinical potential measuring in breast cancer patients future steps needed translate liquid from research practice.